IXICO PLC (AIM:IXI, OTC:PHYOF) said it has secured additional contract orders to support completion of the retrospective analysis of over 6,000 imaging datasets through the Huntington's Disease Imaging Harmonization Consortium (HD-IH).
Huntington's Disease (HD) is a rare, inherited neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities. There are no existing approved disease-modifying therapies for HD, nor interventions that slow disease progression.
The company, which delivers advanced AI analytical insights in neuroscience, said the output of the project will enable current and prospective consortium partners together with their collaborators to develop improved approaches to stratifying patients in HD clinical trials as well as increasing the precision of efficacy measurements of drugs within HD clinical trials.
IXICO is delivering this analysis to the biopharma and charitable foundation consortium members using its proprietary, deep learning-based, IXIQ.Ai analysis platform.
Additional financial contribution has been secured from two partners, where one is a new consortium member and the other an existing consortium member, enabling completion by June 2025. The consortium partners remain open for additional partners to join to benefit from the analysis already undertaken and to further accelerate completion of the project.
In a statement, Giulio Cerroni, chief executive officer of IXICO, commented: "The HD-IH consortium is working on the development of new standards for imaging in HD through the analysis and interpretation of existing HD imaging datasets. We are very excited to build additional momentum in the consortium and look forward to working closely with our existing and new partners towards the development of novel imaging tools that enable the design of more efficient HD clinical trials.
"The development of new imaging standards in this consortium further cements IXICO's position as the leading analysis company for HD as part of its wider portfolio of leading analytical tools to support clinical trials into neurological diseases."
In early trading on Monday, IXICO shares were 3.5% higher at 22p.